Moxifalon (Moxifloxacin)

Moxifloxacin is used to treat bacterial infections affecting the respiratory, sinus, skin, and intra‑abdominal systems.

• Community‑acquired bacterial pneumonia: eradicates the causative pathogens and supports recovery of lung function.
• Acute bacterial sinusitis: reduces sinus inflammation by eliminating the infecting organisms.
• Acute bacterial exacerbation of chronic bronchitis: controls bacterial load to improve breathing and reduce exacerbation severity.
• Complicated skin and skin‑structure infections: provides broad‑spectrum coverage for resistant skin pathogens.
• Complicated intra‑abdominal infections: targets mixed aerobic and anaerobic bacteria to aid surgical and medical management.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA supercoiling and replication. By binding to these enzymes, it prevents DNA strand separation, halting bacterial DNA synthesis and transcription, which leads to rapid bacterial cell death. The dual‑target action provides potent activity against a wide range of Gram‑positive and Gram‑negative organisms.

Adverse reactions may occur with any antibacterial therapy. Patients should be monitored for both frequent and rare events.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: often self‑limiting gastrointestinal disturbance.
• Headache: transient cranial discomfort.
• Dizziness: occasional vertiginous sensation.
• Rash: mild skin erythema or pruritus.
• Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects

• Tendon rupture or inflammation: especially in the Achilles tendon.
• QT interval prolongation: may precipitate cardiac arrhythmias.
• Clostridioides difficile infection: severe colitis following gut flora disruption.
• Anaphylaxis: acute, life‑threatening allergic reaction.
• Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe mucocutaneous blistering.
• Hepatic failure: rare but potentially fatal liver injury.

Moxifloxacin requires careful assessment of patient risk factors before administration.

• Renal impairment: adjust therapy based on renal function.
• Hepatic impairment: monitor liver function tests during treatment.
• QT prolongation risk: avoid in patients with known cardiac conduction disorders.
• Tendon injury: counsel patients to report tendon pain or swelling promptly.
• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Store at room temperature: keep in original container, protect from light and moisture.

Moxifloxacin can interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid)

• Concomitant fluoroquinolones: increased risk of tendon and CNS toxicity.
• QT‑prolonging agents (e.g., macrolides, antiarrhythmics): may cause serious cardiac arrhythmias.
• Antacids or supplements containing magnesium/aluminum/iron: reduce moxifloxacin absorption.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Corticosteroids: combined use may increase tendon rupture risk.